Hetrombopag Combined with TPIAO<sup>?</sup> for Treating Cancer Therapy-Related Thrombocytopenia: A Case Series and Literature Review
-
Published:2024
Issue:04
Volume:14
Page:2477-2485
-
ISSN:2161-8712
-
Container-title:Advances in Clinical Medicine
-
language:
-
Short-container-title:ACM
Publisher
Hans Publishers
Reference14 articles.
1. Exploring and comparing adverse events between PARP inhibitors
2. Shen, Z., Wang, L., Yu, W., et al. (2021) Consensus on Clinical Management of Cancer-Therapy Thrombocytopenia. TUMOR, 41, 812.
3. Understanding, recognizing, and managing toxicities of targeted anticancer therapies
4. Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice
5. A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia